MINERVA NEUROSCIENCE
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.
MINERVA NEUROSCIENCE
Industry:
Biopharma Biotechnology Health Care Neuroscience
Founded:
2007-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.minervaneurosciences.com
Total Employee:
11+
Status:
Active
Contact:
(908)683-8300
Total Funding:
51.28 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Cassava Sciences
Cassava Sciences is a clinical-stage biopharmaceutical company focused on neuroscience.
Destiny Pharma
Destiny Pharma Ltd., a clinical stage pharmaceutical company
HighTide Therapeutics
HighTide Therapeutics is a global clinical-stage biopharmaceutical company.
Hygea Medical Technology
Hygea Medical Technology is a oncology-focused biopharma company.
KBI Biopharma
KBI Biopharma, Inc. (KBI) is a leading development and contract manufacturing organization serving the biopharmaceutical industry. We help
Mereo Biopharma
Mereo is a new UK-based speciality biopharmaceutical company.
Pulmokine
Pulmokine is a privately held biopharmaceutical company
Rion
RION is a clinical-stage regenerative medicine company.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.
YS Biopharma
YS Biopharma is a global, fully integrated bio-pharmaceutical company.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Michael Davidson Chief Medical Officer @ Minerva Neuroscience
Chief Medical Officer
Geoff Race President & Founder @ Minerva Neuroscience
President & Founder
Ramana Kuchibhatla SVP & Head of Research & Development @ Minerva Neuroscience
SVP & Head of Research & Development
2021-09-01
Richard Russell President @ Minerva Neuroscience
President
2017-01-01
Remy Luthringer CEO & president @ Minerva Neuroscience
CEO & president
Jay Saoud Senior Vice President and Head of Research and Development @ Minerva Neuroscience
Senior Vice President and Head of Research and Development
2017-01-01
Founder
Stock Details
Investors List
MetLife
MetLife investment in Post-IPO Equity - Minerva Neuroscience
Sphera Funds Management
Sphera Funds Management investment in Post-IPO Equity - Minerva Neuroscience
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Minerva Neuroscience
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Post-IPO Equity - Minerva Neuroscience
Index Ventures
Index Ventures investment in Post-IPO Equity - Minerva Neuroscience
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Minerva Neuroscience
Highland Capital Partners
Highland Capital Partners investment in Post-IPO Equity - Minerva Neuroscience
Cormorant Asset Management
Cormorant Asset Management investment in Post-IPO Equity - Minerva Neuroscience
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Minerva Neuroscience
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Minerva Neuroscience
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-08 | Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development |
Official Site Inspections
http://www.minervaneurosciences.com
- Host name: 95.70.73.34.bc.googleusercontent.com
- IP address: 34.73.70.95
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Minerva Neuroscience"
Minerva Neurosciences
Our skills in clinical development define our core expertise in central nervous system disorders. We are focused on designing innovative trials with clinical endpoints directly related to patient …See details»
About Us - Minerva Neurosciences
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of product candidates to treat central nervous system (CNS) …See details»
Leadership - Minerva Neurosciences
Dr. Remy Luthringer was named Executive Chairman of the Board on February 5, 2018 and has served as the Chief Executive Officer of Minerva Neurosciences, Inc. since November 2014. …See details»
Investors & Media | Minerva Neurosciences, Inc.
Aug 6, 2024 · The Investor Relations website contains information about Minerva Neurosciences, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Minerva Neurosciences - LinkedIn
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS)...See details»
Minerva Neurosciences Submits New Drug Application to FDA for ...
Mar 2, 2022 · WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on …See details»
Minerva Neurosciences Announces Appointment of Dr. Ramana …
WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development …See details»
Minerva Neurosciences Announces $20 Million in Private …
Jun 28, 2023 · Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) …See details»
Programs Targeting a Range of Unmet Needs in CNS
Minerva Neurosciences is focused on central nervous system (CNS) diseases. Our programs target the treatment of negative symptoms of schizophrenia and Parkinson’s disease, each of which affects millions of people around the world.See details»
Minerva Neurosciences Receives Complete Response Letter from …
Feb 27, 2024 · Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) …See details»
Minerva Neurosciences Announces Update for Three Clinical Trials
Oct 1, 2019 · Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS …See details»
Minerva Neurosciences Receives Complete Response Letter from …
BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of …See details»
Parkinson's Disease - Minerva Neurosciences
According to the World Health Organization, patients meet the clinical diagnosis for Parkinson’s disease when they exhibit two of the four cardinal features of the disease. These are: Postural …See details»
MINERVA NEUROSCIENCES - Overview, News & Similar …
May 1, 2024 · View MINERVA NEUROSCIENCES (www.minervaneurosciences.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar …See details»
Minerva Neurosciences, Inc. (NERV) - Yahoo Finance Canada
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous …See details»
Minerva Neurosciences Announces Results From Phase 3 Trial of ...
WALTHAM, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development …See details»
Minerva Neurosciences Receives Complete Response Letter
Feb 27, 2024 · Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) …See details»
Roluperidone (MIN-101) - Minerva Neurosciences
Roluperidone is a compound that has been shown to block serotonin, sigma and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. We are …See details»
Minerva Neurosciences, Inc. (NERV) - Yahoo Finance
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous …See details»
Minerva Neurosciences Announces Publication of Roluperidone …
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies …See details»